Erectile Dysfunction Following Urethral SurgeryNCT06788704
Tadalafil Daily Used Post Turp
An observational study of Erectile Dysfunction Following Urethral Surgery, run by Kafrelsheikh University at 1 site in Egypt.
Trial summary
to assess the effect of early tadalafil 5 mg once daily on persistent storage lower urinary tract symptoms (LUTS) and erectile function after transurethral resection of the prostate (TURP). Read more about this study
- Who is it for?
- Any age, men only
- Conditions the study is for
- Erectile Dysfunction Following Urethral Surgery
- What is being tested?
- Tadalafil 5mg
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 270 participants
- Where
- 1 siteEgypt
- Study dates
- 1 May 2021to 1 Oct 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Men only
- Child, Adult, Older adult
Study population: Sexual active male patients underwent TURP
Who may be able to join
- sexual active men
Who cannot join
- sexual inactive men
- cardiac patients
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Tadalafil 5 mg on Erection and Persistent Storage Lower Urinary Tract Symptoms After Transurethral Resection of Prostate: a Randmized Controlled Trial
to assess the effect of early tadalafil 5 mg once daily on persistent storage lower urinary tract symptoms (LUTS) and erectile function after transurethral resection of the prostate (TURP).
- Being tested
- Tadalafil 5mg, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tadalafil 5mgDrug
Patient recive tadalafil 5mg once daily early post turp
PlaceboDrug
Patient recive placebo once daily early post turp
| Study group | Role | What they receive |
|---|---|---|
| Patient recive tadalafil 5mg once daily early post turp | Not described Receives: Drug: Tadalafil 5mg | |
| Patient recive placebo once daily early post turp | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess erectile function
Using IIEF score
Measured: One month
Assess erectile function
Usine IIEF score
Measured: 3 month
Secondary outcomes (2)
Assess storage symptoms
Using IPSS Score
Measured: One month
Assess storage symptoms
Using IPSS score
Measured: 3 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2025
- Study start1 May 2021
- Primary completion1 Oct 2022
- Study completion1 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Erectile Dysfunction Following Urethral SurgeryStudies of the same condition, open and under way.
- More trials run by Kafrelsheikh UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 270 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kafrelsheikh University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Elsayed Abdelhalim Elsayed, Kafrelsheikh University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06788704
- Sponsor's protocol ID
- Tadalafil daily used post turp
- Status last verified
- Jan 2025
- First submitted
- 17 Jan 2025
- Last updated
- 28 Jan 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Taha DE, Nabeeh H, Zeinelabden KM, Abdelhalim E, Elmekawy S, Samaha II, Behiry A, Elmoaty AA, Abdelbaky T, Ibrahim A. The effect of tadalafil 5 mg on erection and persistent storage lower urinary tract symptoms after transurethral resection of prostate: a randomized controlled study. Basic Clin Androl. 2025 Jul 1;35(1):27. doi: 10.1186/s12610-025-00273-2.
PubMed 40588736
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Tadalafil 5 mg on Erection and Persistent Storage Lower Urinary Tract Symptoms After Transurethral Resection of Prostate: a Randmized Controlled Trial
- ClinicalTrials.gov ID
- NCT06788704
- Acronym / sponsor ID
- Tadalafil daily used post turp
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 270 participants (actual)
- Lead sponsor
- Kafrelsheikh UniversityUniversity, hospital or other
- Study start
- 1 May 2021 (actual)
- Primary completion
- 1 Oct 2022 (actual)
- Study completion
- 1 Oct 2022 (actual)
- First posted
- 23 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
to assess the effect of early tadalafil 5 mg once daily on persistent storage lower urinary tract symptoms (LUTS) and erectile function after transurethral resection of the prostate (TURP).
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patient recive tadalafil 5mg once daily early post turp | – | Drug: Tadalafil 5mg |
| Patient recive placebo once daily early post turp | – | Drug: Placebo |
Who may qualify
- Sex
- Male only
- Age groups
- Child, Adult, Older adult
- Study population
- Sexual active male patients underwent TURP
Key inclusion criteria (1 listed)
- sexual active men
Key exclusion criteria (2 listed)
- sexual inactive men
- cardiac patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tadalafil 5mgPatient recive tadalafil 5mg once daily early post turp | Drug | Patient recive tadalafil 5mg once daily early post turp |
| PlaceboPatient recive placebo once daily early post turp | Drug | Patient recive placebo once daily early post turp |
Primary outcome
Assess erectile function
Time frame: One month
Using IIEF score
Assess erectile function
Time frame: 3 month
Usine IIEF score
2 secondary outcomes
Assess storage symptoms
Time frame: One month
Assess storage symptoms
Time frame: 3 month
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2025.
- Derived from this study: PubMed 40588736Taha DE, Nabeeh H, Zeinelabden KM, Abdelhalim E, Elmekawy S, Samaha II, Behiry A, Elmoaty AA, Abdelbaky T, Ibrahim A. The effect of tadalafil 5 mg on erection and persistent storage lower urinary tract symptoms after transurethral resection of prostate: a randomized controlled study. Basic Clin Androl. 2025 Jul 1;35(1):27. doi: 10.1186/s12610-025-00273-2.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Erectile Dysfunction Following Urethral Surgery, run by Kafrelsheikh University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess erectile function (time frame: One month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06788704, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2025.